Home About Us Categories Latest Reports News Room Contact us

MEA Whole Exome Sequencing Market - Industry Trends and Forecast to 2029

Report Code: 81659

Industry: Medical Devices & Consumables

Published On: 2022/07/22

Pages: 184

Publisher : Data Bridge Market Research

Middle East & Africa whole exome sequencing (WES) market is projected to register a substantial CAGR of 8.2% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.
Market Segmentation:
Whole Exome Sequencing (WES) Market, By Component (Second generation sequencing and Third-Generation sequencing), Product and Service (systems, kits and services), Application (Drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others ), End User (pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others), Distribution Channel (direct trade, retail sales and others), Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the Middle East & Africa whole exome sequencing (WES) market are:

• Increase in the adoption of whole exome sequencing (WES)
• Growing usage of targeted sequencing methods
Market Segmentation:
Middle East & Africa whole exome sequencing (WES) market is categorized into four notable segment which is Component, Product and Service, Application, End User and Distribution Channel.

• On the basis of component, the global whole exome sequencing (WES) market is segmented into second generation sequencing and third-generation sequencing.

• On the basis of Product and Service, the global whole exome sequencing (WES) market is segmented into systems, kits and services.


• On the basis of Application, the global whole exome sequencing (WES) market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.

• On the basis of End user, the global whole exome sequencing (WES) market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others.

• On the basis of Distribution Channel, the global whole exome sequencing (WES) market is segmented into direct trade, retail sales and others.



Market Players:

The key market players for Middle East & Africa whole exome sequencing (WES) market are listed below:

• GeneDx, LLC
• Psomagen
• Integrated DNA Technologies, Inc., among others.
Market Definition:

Exome sequencing is a method for sequencing a genome’s whole-exome and protein-coding genes. Exome sequencing method entails selecting the DNA segments that code for proteins, then sequencing the exonic DNA with high-throughput DNA sequencing technologies. Exome sequencing is a technique widely used for identifying genetic variations that cause disorders like Miller Syndrome and Alzheimer’s disease among others.
Increasing investment in research based projects and increasing inclination toward next-generation sequencing methods for identification, treatment and monitoring of chronic diseases are boosting up the market growth.
Market Segmentation:
Middle East and Africa whole exome sequencing market is categorized into five notable segments which are based on component, product and service, application, end user and distribution channel. In 2022, second generation sequencing segment is expected to dominate the market due to technological advancement and rising demand of personal genomics.
• On the basis of component, the global whole exome sequencing market is segmented into second generation sequencing and third-generation sequencing.
• On the basis of product and service, the global whole exome sequencing market is segmented into systems, kits and services.
• On the basis of application, the global whole exome sequencing (WES) market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.
• On the basis of end user, the global n whole exome sequencing (WES) market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals, clinical laboratories and others.
• On the basis of distribution channel, the global n whole exome sequencing (WES) market is segmented into direct trade, retail sales and others.

TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET 33
1.4 CURRENCY AND PRICING 35
1.5 LIMITATIONS 35
1.6 MARKETS COVERED 36
2 MARKET SEGMENTATION 39
2.1 MARKETS COVERED 39
2.2 GEOGRAPHICAL SCOPE 40
2.3 YEARS CONSIDERED FOR THE STUDY 41
2.4 DBMR TRIPOD DATA VALIDATION MODEL 42
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
2.6 MULTIVARIATE MODELLING 46
2.7 MARKET APPLICATION COVERAGE GRID 47
2.8 PRODUCT TYPE LIFELINE CURVE 48
2.9 DBMR MARKET POSITION GRID 49
2.10 VENDOR SHARE ANALYSIS 51
2.11 SECONDARY SOURCES 52
2.12 ASSUMPTIONS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHT 57
4.1 PORTER’S FIVE FORCES 58
4.2 PESTEL ANALYSIS 59
4.3 INDUSTRIAL INSIGHTS: 60
4.4 CONCLUSION 61
5 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: REGULATIONS 62
6 MARKET OVERVIEW 64
6.1 DRIVERS 66
6.1.1 GROWING USAGE OF TARGETED SEQUENCING METHODS 66
6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING 66
6.1.3 INCREASING DIAGNOSTICS APPLICATIONS OF WHOLE EXOME SEQUENCING 66
6.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION 67

6.2 RESTRAINTS 68
6.2.1 LESS COMPREHENSIVE COVERAGE OF EXONS 68
6.2.2 CYBER SECURITY CONCERNS IN GENOMICS 68
6.3 OPPORTUNITIES 69
6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER 69
6.3.2 INCREASING PRODUCT LAUNCHES IN RECENT YEARS 69
6.4 CHALLENGES 70
6.4.1 LACK OF SKILLED PROFESSIONALS 70
6.4.2 ETHICAL AND LEGAL ISSUES RELATED TO WHOLE EXOME SEQUENCING 70
7 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT 71
7.1 OVERVIEW 72
7.2 SECOND-GENERATION SEQUENCING 75
7.2.1 SEQUENCING BY SYNTHESIS (SBS) 76
7.2.2 SEQUENCING BY HYBRIDIZATION (SBH) AND SEQUENCING BY LIGATION (SBL) 76
7.3 THIRD-GENERATION SEQUENCING 77
8 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE 78
8.1 OVERVIEW 79
8.2 SYSTEMS 82
8.2.1 HISEQ SERIES 83
8.2.1.1 HISEQ 2500 83
8.2.1.2 HISEQ 1500 83
8.2.2 MISEQ SERIES 83
8.2.3 ION TORRENT PLATFORMS 84
8.2.3.1 ION PROTON 84
8.2.3.2 ION PGM 84
8.2.4 OTHERS 84
8.3 KITS 84
8.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING, AND SIZE SELECTION KITS 85
8.3.2 LIBRARY PREPARATION KITS 85
8.3.3 TARGET ENRICHMENT KITS 86
8.3.4 OTHERS 86
8.4 SERVICES 86
8.4.1 SEQUENCING SERVICES 87
8.4.2 DATA ANALYSIS (BIOINFORMATICS) SERVICES 87
8.4.3 OTHERS 87

9 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION 88
9.1 OVERVIEW 89
9.2 DRUG DISCOVERY AND DEVELOPMENT 92
9.3 AGRICULTURE & ANIMAL RESEARCH 93
9.4 DIAGNOSTICS 93
9.5 PERSONALIZED MEDICINE 94
9.6 OTHERS 95
10 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY END USER 96
10.1 OVERVIEW 97
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 100
10.3 ACADEMIC & RESEARCH INSTITUTES 101
10.4 HOSPITALS AND CLINICS 101
10.5 CLINICAL LABORATORIES 102
10.6 OTHERS 103
11 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL 104
11.1 OVERVIEW 105
11.2 DIRECT TRADE 108
11.3 RETAIL SALES 108
11.4 OTHERS 110
12 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY REGION 111
12.1 MIDDLE EAST AND AFRICA 112
12.1.1 SOUTH AFRICA 120
12.1.2 SAUDI ARABIA 124
12.1.3 U.A.E 128
12.1.4 ISRAEL 131
12.1.5 EGYPT 134
12.1.6 REST OF MIDDLE EAST AND AFRICA 137
13 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: COMPANY LANDSCAPE 138
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 138

14 COMPANY PROFILE 139
14.1 PERKINELMER GENOMICS (A SUBSIDIARY OF PERKINELMER INC.) 139
14.1.1 COMPANY SNAPSHOT 139
14.1.2 REVENUE ANALYSIS 139
14.1.3 COM PANY SHARE ANALYSIS 140
14.1.4 PRODUCT PORTFOLIO 140
14.1.5 RECENT DEVELOPMENTS 140
14.2 MERCK KGAA 142
14.2.1 COMPANY SNAPSHOT 142
14.2.2 REVENUE ANALYSIS 142
14.2.3 COM PANY SHARE ANALYSIS 143
14.2.4 PRODUCT PORTFOLIO 143
14.2.5 RECENT DEVELOPMENTS 143
14.3 EXODX (A PART OF BIO-TECHNE) 144
14.3.1 COMPANY SNAPSHOT 144
14.3.2 REVENUE ANALYSIS 144
14.3.3 COM PANY SHARE ANALYSIS 145
14.3.4 PRODUCT PORTFOLIO 145
14.3.5 RECENT DEVELOPMENTS 145
14.4 THERMO FISHER SCIENTIFIC INC. 146
14.4.1 COMPANY SNAPSHOT 146
14.4.2 REVENUE ANALYSIS 146
14.4.3 COM PANY SHARE ANALYSIS 147
14.4.4 PRODUCT PORTFOLIO 147
14.4.5 RECENT DEVELOPMENTS 147
14.5 FOUNDATION MEDICINE, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD) 148
14.5.1 COMPANY SNAPSHOT 148
14.5.2 REVENUE ANALYSIS 148
14.5.3 COM PANY SHARE ANALYSIS 149
14.5.4 PRODUCT PORTFOLIO 149
14.5.5 RECENT DEVELOPMENTS 149
14.6 AZENTA US, INC. 151
14.6.1 COMPANY SNAPSHOT 151
14.6.2 PRODUCT PORTFOLIO 151
14.6.3 RECENT DEVELOPMENTS 151
14.7 BECKMAN COULTER, INC 153
14.7.1 COMPANY SNAPSHOT 153
14.7.2 REVENUE ANALYSIS 153
14.7.3 PRODUCT PORTFOLIO 154
14.7.4 RECENT DEVELOPMENTS 154
14.8 BIONEER CORPORATION 155
14.8.1 COMPANY SNAPSHOT 155
14.8.2 REVENUE ANALYSIS 155
14.8.3 PRODUCT PORTFOLIO 156
14.8.4 RECENT DEVELOPMENTS 156
14.9 CD GENOMICS 157
14.9.1 COMPANY SNAPSHOT 157
14.9.2 PRODUCT PORTFOLIO 157
14.9.3 RECENT DEVELOPMENTS 157
14.10 CEGAT GMBH 158
14.10.1 COMPANY SNAPSHOT 158
14.10.2 PRODUCT PORTFOLIO 158
14.10.3 RECENT DEVELOPMENTS 158
14.11 EUROFINS SCIENTIFIC 159
14.11.1 COMPANY SNAPSHOT 159
14.11.2 REVENUE ANALYSIS 159
14.11.3 PRODUCT PORTFOLIO 160
14.11.4 RECENT DEVELOPMENTS 160
14.12 GENEDX, LLC 161
14.12.1 COMPANY SNAPSHOT 161
14.12.2 PRODUCT PORTFOLIO 161
14.12.3 RECENT DEVELOPMENTS 161
14.13 GENEFIRST LIMITED. 163
14.13.1 COMPANY SNAPSHOT 163
14.13.2 PRODUCT PORTFOLIO 163
14.13.3 RECENT DEVELOPMENTS 163
14.14 ILLUMINA, INC 165
14.14.1 COMPANY SNAPSHOT 165
14.14.2 REVENUE ANALYSIS 165
14.14.3 PRODUCT PORTFOLIO 166
14.14.4 RECENT DEVELOPMENTS 166
14.15 INTEGRATED DNA TECHNOLOGIES, INC. 168
14.15.1 COMPANY SNAPSHOT 168
14.15.2 PRODUCT PORTFOLIO 168
14.15.3 RECENT DEVELOPMENTS 168
14.16 MERIDIAN BIOSCIENCE, INC. 170
14.16.1 COMPANY SNAPSHOT 170
14.16.2 REVENUE ANALYSIS 170
14.16.3 PRODUCT PORTFOLIO 171
14.16.4 RECENT DEVELOPMENTS 171
14.17 PSOMAGEN 172
14.17.1 COMPANY SNAPSHOT 172
14.17.2 REVENUE ANALYSIS 172
14.17.3 PRODUCT PORTFOLIO 172
14.17.4 RECENT DEVELOPMENTS 173
14.18 QIAGEN 174
14.18.1 COMPANY SNAPSHOT 174
14.18.2 REVENUE ANALYSIS 174
14.18.3 PRODUCT PORTFOLIO 175
14.18.4 RECENT DEVELOPMENTS 175
14.19 SOPHIA GENETICS 176
14.19.1 COMPANY SNAPSHOT 176
14.19.2 REVENUE ANALYSIS 176
14.19.3 PRODUCT PORTFOLIO 177
14.19.4 RECENT DEVELOPMENTS 177
14.20 TWIST BIOSCIENCE 178
14.20.1 COMPANY SNAPSHOT 178
14.20.2 REVENUE ANALYSIS 178
14.20.3 PRODUCT PORTFOLIO 179
14.20.4 RECENT DEVELOPMENTS 179
15 QUESTIONNAIRE 181
16 RELATED REPORTS 184